During pregnancy, the muscles of the uterus are relatively inactive. A switch to an activated state capable of strong contractions is therefore essential prior to the onset of labor. Kathleen Martin and colleagues, at Dartmouth Medical School, Lebanon, have now provided new insight into the events that prime the uterine muscles for contraction, something that they hope might have implications for the development of therapies for preterm labor (i.e., labor that occurs before 37 weeks of pregnancy), the most serious complication of pregnancy in developed countries.
In the study, when the protein IP on the surface of muscle cells in human uterine tissue strips obtained from pregnant women undergoing Caesarean delivery prior to the onset of natural labor was stimulated by agonist chemicals, it induced the upregulation of proteins involved in muscle contraction. Further, the same chemicals increased the contraction of these tissue strips in response to the hormone oxytocin. The authors therefore conclude that the molecule that normally binds IP in vivo, prostacyclin, primes the muscles in the human uterus, allowing for strong contractions during labor. As Michael Taggart, at Newcastle University, United Kingdom, and colleagues discuss in an accompanying commentary, these data might be viewed by many as contentious, because prostacyclin is a smooth muscle relaxant. However, they do provide an explanation for the paradoxical observation that one of the major signaling molecules produced by the uterus just prior to labor is prostacyclin.
TITLE: Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition
Kathleen A. Martin
Dartmouth Medical School, Lebanon, New Hampshire, USA.
Phone: (603) 650-7439; Fax: (603) 650-4928; E-mail: firstname.lastname@example.org.
View the PDF of this article at: https://www.the-jci.org/article.php?id=33800
TITLE: Possible dual roles for prostacyclin in human pregnancy and labor
Michael J. Taggart
Newcastle University, Newcastle upon Tyne, United Kingdom.
Phone: 44-191-222-6988; Fax: 44-191-222-5066; E-mail: Michael.email@example.com.
View the PDF of this article at: https://www.the-jci.org/article.php?id=37785
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.